DAVENPORT & Co LLC - CELGENE CORP ownership

CELGENE CORP's ticker is CELGZ and the CUSIP is 151020112. A total of 19 filers reported holding CELGENE CORP in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
DAVENPORT & Co LLC ownership history of CELGENE CORP
ValueSharesWeighting
Q3 2019$70,000
-1.4%
113,670
-1.0%
0.00%0.0%
Q2 2019$71,000
-44.1%
114,8700.0%0.00%
-50.0%
Q1 2019$127,000
+144.2%
114,8700.0%0.00%
+100.0%
Q4 2018$52,000
-72.9%
114,870
-4.2%
0.00%
-50.0%
Q3 2018$192,000
+346.5%
119,8700.0%0.00%
+100.0%
Q2 2018$43,000
-99.9%
119,8700.0%0.00%
Q1 2018$34,762,000
-70.1%
119,8700.0%0.00%
-100.0%
Q4 2017$116,274,000
-34.8%
119,870
+1.8%
0.00%
-50.0%
Q3 2017$178,456,000
+22.3%
117,7460.0%0.00%0.0%
Q2 2017$145,946,000
+32.4%
117,746
+10.0%
0.00%0.0%
Q1 2017$110,230,000
+100109.1%
107,0200.0%0.00%0.0%
Q4 2016$110,000
-99.9%
107,020
+8.0%
0.00%0.0%
Q3 2016$103,064,000
-30.2%
99,100
-2.0%
0.00%0.0%
Q2 2016$147,616,000
+28.4%
101,100
+2.0%
0.00%0.0%
Q1 2016$114,956,000
-0.8%
99,100
+2.6%
0.00%0.0%
Q4 2015$115,920,000
-27.0%
96,600
-2.0%
0.00%
-33.3%
Q3 2015$158,746,000
-22.6%
98,6000.0%0.00%0.0%
Q2 2015$205,088,000
-30.0%
98,6000.0%0.00%
-40.0%
Q1 2015$292,842,000
-0.3%
98,600
+5.8%
0.01%0.0%
Q4 2014$293,580,000
-7.1%
93,2000.0%0.01%
-16.7%
Q3 2014$315,948,000
+71.2%
93,200
+31.3%
0.01%
+100.0%
Q2 2014$184,600,000
+1.1%
71,000
+9.2%
0.00%0.0%
Q1 2014$182,650,000
+11.5%
65,000
+8.3%
0.00%0.0%
Q4 2013$163,800,00060,0000.00%
Other shareholders
CELGENE CORP shareholders Q3 2017
NameSharesValueWeighting ↓
Birchview Capital, LP 238,214$348,0000.25%
FCG ADVISORS, LLC 299,943$438,0000.14%
United Asset Strategies, Inc. 112,300$164,0000.06%
MESSNER & SMITH THEME VALUE INVESTMENT MANAGEMENT LTD /CA/ 15,000$22,0000.04%
Cannell & Co. 333,865$487,0000.02%
ASCEND CAPITAL, LLC 50,714$74,0000.01%
CSS LLC/IL 17,278$25,0000.00%
DAVENPORT & Co LLC 101,100$147,616,0000.00%
FIFTH THIRD BANCORP 52$00.00%
BANK OF AMERICA CORP /DE/ 20,241$29,0000.00%
View complete list of CELGENE CORP shareholders